A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I)
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I)
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 490 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Actual Study Start Date: February 19, 2020
Estimated Primary Completion Date: May 2022
Estimated Study Completion Date: May 2023
Arms:
- Experimental: Bimekizumab dosing regimen 1
- Experimental: Bimekizumab dosing regimen 2
- Experimental: Bimekizumab dosing regimen 3
- Placebo Comparator: Placebo Group
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 490 |
| Actual Study start date | 19 February 2020 |
| Estimated Study Completion Date | 01 May 2023 |